Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "LTI"

2564 News Found

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders
R&D | October 22, 2025

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation


Roquette opens health and pharma solutions innovation center in Brazil
R&D | October 20, 2025

Roquette opens health and pharma solutions innovation center in Brazil

This new facility strengthens Latin America as a collaborative hub


FDA approves Alembic’s Triamcinolone Acetonide injectable suspension USP, 40 mg/mL
Drug Approval | October 19, 2025

FDA approves Alembic’s Triamcinolone Acetonide injectable suspension USP, 40 mg/mL

Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions


Gujarat Themis Biosyn doubles fermentation production capacity at Vapi
News | October 19, 2025

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi

With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL


IKS Health announces generative AI platform built on Google cloud
Digitisation | October 18, 2025

IKS Health announces generative AI platform built on Google cloud

IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow


Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin
News | October 18, 2025

Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program


Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million
News | October 17, 2025

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million

Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio


Merck KGaA  to acquire chromatography business of JSR Life Sciences
News | October 16, 2025

Merck KGaA to acquire chromatography business of JSR Life Sciences

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions


AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025
Clinical Trials | October 14, 2025

AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025

New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers